Skip to main content
Figure 13 | Journal of Neuroinflammation

Figure 13

From: Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer’s disease pathology in TgSwDI and 3xTg mouse models

Figure 13

Quantitation of phosphorylated tau in the soluble brain homogenate by Western blot using PHF1 for 3xTg mice. (A) Upper: Western blot using PHF1. Lower: Membrane stained with Fast Green before being probed with PHF1, shown to illustrate that there was an equal protein load in each of the lanes. (B) Densitometric quantitation of the specific, approximately 60 kDa, PHF1 immunoreactive band, with a 50% reduction for the pBri-treated 3xTg mice (P < 0.0001 by an unpaired two-tailed t-test). (C) Quantitation of phosphorylated tau (Thr231) and (D) quantitation of total tau using a Meso Scale Discovery (MSD) system that utilizes electrochemiluminescence analysis. There is a significant reduction of phosphorylated tau (Thr231; P = 0.019 by two-tailed t-test) of 15%. There is no significant difference in total tau when comparing pBri-immunized and control 3xTg mice. MSD, Meso Scale Discovery.

Back to article page